Skip to main content
. 2023 Aug 11;299(9):105155. doi: 10.1016/j.jbc.2023.105155

Figure 6.

Figure 6

Silencing of Gli2 inMC3T3preosteoblast does not alter EPZ6438-mediated osteogenic differentiation. Diagram of the experimental protocol for treatment of MC3T3 with siCtrl or siGli2 and with vehicle (Veh) or 2.5 μM EPZ6438 shown in panels B–D (A). Gli1 mRNA levels as evaluated by RT-qPCR on day 2 (B). RT-qPCR analysis for bone-related markers relative to Gapdh (set at 100) on day 9 (C). Alizarin red staining on day 41 (D). All error bars represent ±SD of three experimental replicates. (ns = not significant, ∗p ≤ 0.05, ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001, and ∗∗∗∗p ≤ 0.0001). RT-qPCR, real-time quantitative PCR.